PTC Therapeutics (PTCT) Receives Analyst Rating

PTC Therapeutics (PTCT) : 1 brokerage houses believe that PTC Therapeutics (PTCT) is a Strong Buy at current levels. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on PTC Therapeutics (PTCT). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 6 Wall Street Analysts endorse the stock as a Hold with a rating of 2.67.

PTC Therapeutics (PTCT) : Average target price received by PTC Therapeutics (PTCT) is $11.4 with an expected standard deviation of $5.03. The most aggressive target on the stock is $20, whereas the most downbeat target is $7. 5 financial analysts are currently covering the stock.


Also, Major Brokerage house, Citigroup maintains its ratings on PTC Therapeutics (NASDAQ:PTCT). In the latest research report, Citigroup raises the target price from $8 per share to $9 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on August 8, 2016.

PTC Therapeutics (NASDAQ:PTCT): The stock opened in the green at $9.03 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $9.05 and a low of $8.641 for the day. The stock did not find buyers even at the lows and closed at $8.83 recording a loss of -2.11%. 818,341 shares exchanged hands during the trading day. The stock had closed at $9.02 in the previous days trading.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *